{"id":1083,"date":"2022-01-05T22:18:33","date_gmt":"2022-01-06T05:18:33","guid":{"rendered":"https:\/\/blog.medcram.com\/?p=1083"},"modified":"2022-02-28T22:50:25","modified_gmt":"2022-03-01T05:50:25","slug":"covid-19-updates-pfizer-covid-19-fda-authorized-pill-paxlovid-explained-and-update-on-monoclonal-antibodies-and-omicron-variant","status":"publish","type":"post","link":"https:\/\/blog.medcram.com\/covid-19\/covid-19-updates-pfizer-covid-19-fda-authorized-pill-paxlovid-explained-and-update-on-monoclonal-antibodies-and-omicron-variant\/","title":{"rendered":"COVID-19 Updates &#8211; Pfizer COVID 19 FDA Authorized Pill &#8220;Paxlovid&#8221; Explained, and an Update on Monoclonal Antibodies and the Omicron Variant."},"content":{"rendered":"<p style=\"text-align: center;\"><iframe loading=\"lazy\" title=\"YouTube video player\" src=\"https:\/\/www.youtube.com\/embed\/GMMTw0MAT-8\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/p>\n<p style=\"text-align: center;\"><iframe loading=\"lazy\" title=\"YouTube video player\" src=\"https:\/\/www.youtube.com\/embed\/HnFjVXmiglk\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/p>\n<p>&nbsp;<\/p>\n<p style=\"text-align: left;\"><span style=\"font-weight: 400;\">Professor Roger Seheult, MD of MedCram, examines Paxlovid, how it works, and its efficacy against severe disease and hospitalization. He also takes a look at monoclonal antibodies and how they interact with the Omicron variant and can assist with avoiding hospitalization and severe illness.\u00a0<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><b>Pfizer COVID 19 FDA Authorized Pill &#8220;Paxlovid&#8221; Explained<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">In this <\/span><a href=\"https:\/\/youtu.be\/GMMTw0MAT-8\"><span style=\"font-weight: 400;\">144th<\/span><\/a><span style=\"font-weight: 400;\"> update video, Roger Seheult, MD of MedCram illustrates how Pfizer&#8217;s Paxlovid works, its efficacy, and its side effects. An oral medication that received FDA emergency use authorization to help reduce severe illness and hospitalization from COVID-19, Paxlovid consists of 1 tablet of Ritonavir and 2 tablets of Nirmatrelvir per dose. Dr. Seheult reviews how the SARS-COV-2 (COVID-19) virus infects and reproduces in human cells. He then shows how Paxlovid acts as a protease inhibitor by binding to protease and preventing its replication in the cell. For more information on the biochemistry and synthesis of Paxlovid, see this <\/span><a href=\"https:\/\/youtu.be\/HHzaiAwJpfQ\"><span style=\"font-weight: 400;\">video<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Dr. Seheult reviews the Pfizer Phase 2 and 3 clinical trials, a randomized, placebo-controlled double-blind study of 1219 participants. Clinical trial data for Paxlovid show that if taken within 3 days of symptom onset, hospitalizations and death were reduced by 89% and if taken within 5 days of symptom onset, reduced by 85%.\u00a0 However, there was no data available for patients treated with Paxlovid beyond 5 days of symptom onset. More information on this trial can be found in this <\/span><a href=\"https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizers-novel-covid-19-oral-antiviral-treatment-candidate\"><span style=\"font-weight: 400;\">press release<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Next, he covers Paxlovid availability. With over a million new cases of Omicron predicted in early 2022, Pfizer produced 180,000 doses in 2021 and plans to produce 120 million doses for worldwide distribution in 2022. He notes that the US purchased 10 million doses for 5.3 billion US dollars. Refer to this <\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7331567\/\"><span style=\"font-weight: 400;\">article<\/span><\/a><span style=\"font-weight: 400;\"> for more information on Paxlovid\u00e5, and this <\/span><a href=\"https:\/\/www.pharmaceutical-technology.com\/special-focus\/covid-19\/pfizer-paxlovid-effective-severe-covid-19-omicron-variant\/\"><span style=\"font-weight: 400;\">article<\/span><\/a><span style=\"font-weight: 400;\"> on Paxlovid\u2019s efficacy <\/span><span style=\"font-weight: 400;\">against severe disease and Omicron variant.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><b>Monoclonal Antibodies: Omicron Update<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">In our <\/span><a href=\"https:\/\/youtu.be\/HnFjVXmiglk\"><span style=\"font-weight: 400;\">145th<\/span><\/a><span style=\"font-weight: 400;\"> update video, Roger Seheult, MD of MedCram examines monoclonal antibodies, how they interact with the omicron variant, and how they can assist with reducing hospitalization and severe illness.\u00a0 First, he takes a look at how the SARS-COV-2 (COVID-19) virus infects human cells. He explains how monoclonal antibodies bind to the spike protein thereby neutralizing the virus and rendering it unable to attach to the ACE-2 receptors. Next, he identifies the key requirements for effective use of antibodies. These include symptomatic infection with COVID-19 for less than 10 days and risk for progression to hospitalization and\/or\u00a0 severe illness due to comorbid risk factors. There are currently 3 monoclonal antibody infusions that have been given emergency authorization for use by the FDA from Lilly, Regeneron and GSK. More details on these are found in this <\/span><a href=\"http:\/\/infusioncenter.org\/wp-content\/uploads\/2021\/11\/SOTROVIMAB-EUA.pdf\"><span style=\"font-weight: 400;\">fact sheet<\/span><\/a><span style=\"font-weight: 400;\">, <\/span><a href=\"https:\/\/www.covid19treatmentguidelines.nih.gov\/tables\/mab-data\/\"><span style=\"font-weight: 400;\">clinical data<\/span><\/a><span style=\"font-weight: 400;\">, and <\/span><a href=\"https:\/\/www.biorxiv.org\/content\/10.1101\/2021.03.09.434607v10.full.pdf\"><span style=\"font-weight: 400;\">article<\/span><\/a><span style=\"font-weight: 400;\">.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">He notes that due to changes in the spike protein of the virus, such as in a variant like Omicron, the monoclonal antibodies may not be able to bind and lose efficacy in neutralizing the Omicron variant.\u00a0 It has been found that the monoclonal antibody infusions from both Lilly and Regeneron have no significant efficacy against the Omicron variant, whereas GSK infusion does neutralize the Omicron variant.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The doctor also mentions other COVID-19 treatment options available including <\/span><a href=\"https:\/\/youtu.be\/GMMTw0MAT-8\"><span style=\"font-weight: 400;\">Paxlovid<\/span><\/a><span style=\"font-weight: 400;\"> and <\/span><a href=\"https:\/\/youtu.be\/aI0xGfITaas\"><span style=\"font-weight: 400;\">Molnupiravir<\/span><\/a><span style=\"font-weight: 400;\">, but mentions they only have a 5-day symptomatic treatment window vs. 10 days using monoclonal antibodies. He references this video from MedCram on <\/span><a href=\"https:\/\/youtu.be\/vN30emwcNS4\"><span style=\"font-weight: 400;\">If You Get COVID-19: Optimizing the Immune System<\/span><\/a><span style=\"font-weight: 400;\"> for more information.\u00a0<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><b>Stay Tuned for More COVID-19 Updates\u00a0<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Our COVID-19 videos are always available for <\/span><i><span style=\"font-weight: 400;\">free <\/span><\/i><span style=\"font-weight: 400;\">(and ad-free) at<\/span><a href=\"https:\/\/www.medcram.com\/collections?category=covid-19-SARS-CoV-2\"> <span style=\"font-weight: 400;\">MedCram.com<\/span><\/a><span style=\"font-weight: 400;\">. In addition, check out our full library of courses and lectures on subjects ranging from<\/span> <a href=\"https:\/\/www.medcram.com\/courses\/hypertension-explained-clearly-2\"><span style=\"font-weight: 400;\">Hypertension Explained Clearly<\/span><\/a><span style=\"font-weight: 400;\"> to<\/span><a href=\"https:\/\/www.medcram.com\/courses\/sleep-apnea-explained-clearly\"> <span style=\"font-weight: 400;\">Sleep Apnea Explained Clearly<\/span><\/a><span style=\"font-weight: 400;\"> Course and many more!<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Meanwhile, you can find all of our COVID-19 videos compiled <\/span><a href=\"https:\/\/www.medcram.com\/collections?category=covid-19-SARS-CoV-2\"><span style=\"font-weight: 400;\">here<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content -->","protected":false},"excerpt":{"rendered":"<p>&nbsp; Professor Roger Seheult, MD of MedCram, examines Paxlovid, how it works, and its efficacy against severe disease and hospitalization. He also takes a look at monoclonal antibodies and how they interact with the Omicron variant and can assist with avoiding hospitalization and severe illness.\u00a0 &nbsp; Pfizer COVID 19 FDA Authorized Pill &#8220;Paxlovid&#8221; Explained In&hellip;<!-- AddThis Advanced Settings generic via filter on get_the_excerpt --><!-- AddThis Share Buttons generic via filter on get_the_excerpt --><\/p>\n","protected":false},"author":8,"featured_media":1085,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[25,16],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>COVID-19 Updates - Pfizer COVID 19 FDA Authorized Pill &quot;Paxlovid&quot; Explained, and an Update on Monoclonal Antibodies and the Omicron Variant. - Medcram Blog<\/title>\n<meta name=\"description\" content=\"Professor Roger Seheult, MD of MedCram, examines Paxlovid, how it works, and its efficacy against severe disease and hospitalization. He also takes a look at monoclonal antibodies and how they interact with the Omicron variant and can assist with avoiding hospitalization and severe illness.\u00a0\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blog.medcram.com\/covid-19\/covid-19-updates-pfizer-covid-19-fda-authorized-pill-paxlovid-explained-and-update-on-monoclonal-antibodies-and-omicron-variant\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"COVID-19 Updates - Pfizer COVID 19 FDA Authorized Pill &quot;Paxlovid&quot; Explained, and an Update on Monoclonal Antibodies and the Omicron Variant. - Medcram Blog\" \/>\n<meta property=\"og:description\" content=\"Professor Roger Seheult, MD of MedCram, examines Paxlovid, how it works, and its efficacy against severe disease and hospitalization. He also takes a look at monoclonal antibodies and how they interact with the Omicron variant and can assist with avoiding hospitalization and severe illness.\u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blog.medcram.com\/covid-19\/covid-19-updates-pfizer-covid-19-fda-authorized-pill-paxlovid-explained-and-update-on-monoclonal-antibodies-and-omicron-variant\/\" \/>\n<meta property=\"og:site_name\" content=\"Medcram Blog\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/MedCram\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-01-06T05:18:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-03-01T05:50:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blog.medcram.com\/wp-content\/uploads\/2022\/01\/MedCramAntibodies.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Betty Seheult\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@medcramvideos\" \/>\n<meta name=\"twitter:site\" content=\"@medcramvideos\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Betty Seheult\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/blog.medcram.com\/covid-19\/covid-19-updates-pfizer-covid-19-fda-authorized-pill-paxlovid-explained-and-update-on-monoclonal-antibodies-and-omicron-variant\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/blog.medcram.com\/covid-19\/covid-19-updates-pfizer-covid-19-fda-authorized-pill-paxlovid-explained-and-update-on-monoclonal-antibodies-and-omicron-variant\/\"},\"author\":{\"name\":\"Betty Seheult\",\"@id\":\"https:\/\/blog.medcram.com\/#\/schema\/person\/0f1abd9ef5d4bf6b5fe0b0d50b9fd9c2\"},\"headline\":\"COVID-19 Updates &#8211; Pfizer COVID 19 FDA Authorized Pill &#8220;Paxlovid&#8221; Explained, and an Update on Monoclonal Antibodies and the Omicron Variant.\",\"datePublished\":\"2022-01-06T05:18:33+00:00\",\"dateModified\":\"2022-03-01T05:50:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/blog.medcram.com\/covid-19\/covid-19-updates-pfizer-covid-19-fda-authorized-pill-paxlovid-explained-and-update-on-monoclonal-antibodies-and-omicron-variant\/\"},\"wordCount\":627,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/blog.medcram.com\/#organization\"},\"articleSection\":[\"COVID-19\",\"Infectious Disease\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/blog.medcram.com\/covid-19\/covid-19-updates-pfizer-covid-19-fda-authorized-pill-paxlovid-explained-and-update-on-monoclonal-antibodies-and-omicron-variant\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/blog.medcram.com\/covid-19\/covid-19-updates-pfizer-covid-19-fda-authorized-pill-paxlovid-explained-and-update-on-monoclonal-antibodies-and-omicron-variant\/\",\"url\":\"https:\/\/blog.medcram.com\/covid-19\/covid-19-updates-pfizer-covid-19-fda-authorized-pill-paxlovid-explained-and-update-on-monoclonal-antibodies-and-omicron-variant\/\",\"name\":\"COVID-19 Updates - Pfizer COVID 19 FDA Authorized Pill \\\"Paxlovid\\\" Explained, and an Update on Monoclonal Antibodies and the Omicron Variant. - Medcram Blog\",\"isPartOf\":{\"@id\":\"https:\/\/blog.medcram.com\/#website\"},\"datePublished\":\"2022-01-06T05:18:33+00:00\",\"dateModified\":\"2022-03-01T05:50:25+00:00\",\"description\":\"Professor Roger Seheult, MD of MedCram, examines Paxlovid, how it works, and its efficacy against severe disease and hospitalization. He also takes a look at monoclonal antibodies and how they interact with the Omicron variant and can assist with avoiding hospitalization and severe illness.\u00a0\",\"breadcrumb\":{\"@id\":\"https:\/\/blog.medcram.com\/covid-19\/covid-19-updates-pfizer-covid-19-fda-authorized-pill-paxlovid-explained-and-update-on-monoclonal-antibodies-and-omicron-variant\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/blog.medcram.com\/covid-19\/covid-19-updates-pfizer-covid-19-fda-authorized-pill-paxlovid-explained-and-update-on-monoclonal-antibodies-and-omicron-variant\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/blog.medcram.com\/covid-19\/covid-19-updates-pfizer-covid-19-fda-authorized-pill-paxlovid-explained-and-update-on-monoclonal-antibodies-and-omicron-variant\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/blog.medcram.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"COVID-19\",\"item\":\"https:\/\/blog.medcram.com\/category\/covid-19\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"COVID-19 Updates &#8211; Pfizer COVID 19 FDA Authorized Pill &#8220;Paxlovid&#8221; Explained, and an Update on Monoclonal Antibodies and the Omicron Variant.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/blog.medcram.com\/#website\",\"url\":\"https:\/\/blog.medcram.com\/\",\"name\":\"Medcram Blog\",\"description\":\"Medcram Blog\",\"publisher\":{\"@id\":\"https:\/\/blog.medcram.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/blog.medcram.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/blog.medcram.com\/#organization\",\"name\":\"MedCram\",\"url\":\"https:\/\/blog.medcram.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/blog.medcram.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/blog.medcram.com\/wp-content\/uploads\/2017\/05\/logo.png\",\"contentUrl\":\"https:\/\/blog.medcram.com\/wp-content\/uploads\/2017\/05\/logo.png\",\"width\":152,\"height\":89,\"caption\":\"MedCram\"},\"image\":{\"@id\":\"https:\/\/blog.medcram.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/MedCram\/\",\"https:\/\/twitter.com\/medcramvideos\",\"https:\/\/www.instagram.com\/medcram\/\",\"https:\/\/www.youtube.com\/c\/medcram\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/blog.medcram.com\/#\/schema\/person\/0f1abd9ef5d4bf6b5fe0b0d50b9fd9c2\",\"name\":\"Betty Seheult\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/blog.medcram.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2ed8bbd19f04d10eaff8a77705d7f213?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2ed8bbd19f04d10eaff8a77705d7f213?s=96&d=mm&r=g\",\"caption\":\"Betty Seheult\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"COVID-19 Updates - Pfizer COVID 19 FDA Authorized Pill \"Paxlovid\" Explained, and an Update on Monoclonal Antibodies and the Omicron Variant. - Medcram Blog","description":"Professor Roger Seheult, MD of MedCram, examines Paxlovid, how it works, and its efficacy against severe disease and hospitalization. He also takes a look at monoclonal antibodies and how they interact with the Omicron variant and can assist with avoiding hospitalization and severe illness.\u00a0","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blog.medcram.com\/covid-19\/covid-19-updates-pfizer-covid-19-fda-authorized-pill-paxlovid-explained-and-update-on-monoclonal-antibodies-and-omicron-variant\/","og_locale":"en_US","og_type":"article","og_title":"COVID-19 Updates - Pfizer COVID 19 FDA Authorized Pill \"Paxlovid\" Explained, and an Update on Monoclonal Antibodies and the Omicron Variant. - Medcram Blog","og_description":"Professor Roger Seheult, MD of MedCram, examines Paxlovid, how it works, and its efficacy against severe disease and hospitalization. He also takes a look at monoclonal antibodies and how they interact with the Omicron variant and can assist with avoiding hospitalization and severe illness.\u00a0","og_url":"https:\/\/blog.medcram.com\/covid-19\/covid-19-updates-pfizer-covid-19-fda-authorized-pill-paxlovid-explained-and-update-on-monoclonal-antibodies-and-omicron-variant\/","og_site_name":"Medcram Blog","article_publisher":"https:\/\/www.facebook.com\/MedCram\/","article_published_time":"2022-01-06T05:18:33+00:00","article_modified_time":"2022-03-01T05:50:25+00:00","og_image":[{"width":1280,"height":720,"url":"https:\/\/blog.medcram.com\/wp-content\/uploads\/2022\/01\/MedCramAntibodies.jpeg","type":"image\/jpeg"}],"author":"Betty Seheult","twitter_card":"summary_large_image","twitter_creator":"@medcramvideos","twitter_site":"@medcramvideos","twitter_misc":{"Written by":"Betty Seheult","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blog.medcram.com\/covid-19\/covid-19-updates-pfizer-covid-19-fda-authorized-pill-paxlovid-explained-and-update-on-monoclonal-antibodies-and-omicron-variant\/#article","isPartOf":{"@id":"https:\/\/blog.medcram.com\/covid-19\/covid-19-updates-pfizer-covid-19-fda-authorized-pill-paxlovid-explained-and-update-on-monoclonal-antibodies-and-omicron-variant\/"},"author":{"name":"Betty Seheult","@id":"https:\/\/blog.medcram.com\/#\/schema\/person\/0f1abd9ef5d4bf6b5fe0b0d50b9fd9c2"},"headline":"COVID-19 Updates &#8211; Pfizer COVID 19 FDA Authorized Pill &#8220;Paxlovid&#8221; Explained, and an Update on Monoclonal Antibodies and the Omicron Variant.","datePublished":"2022-01-06T05:18:33+00:00","dateModified":"2022-03-01T05:50:25+00:00","mainEntityOfPage":{"@id":"https:\/\/blog.medcram.com\/covid-19\/covid-19-updates-pfizer-covid-19-fda-authorized-pill-paxlovid-explained-and-update-on-monoclonal-antibodies-and-omicron-variant\/"},"wordCount":627,"commentCount":0,"publisher":{"@id":"https:\/\/blog.medcram.com\/#organization"},"articleSection":["COVID-19","Infectious Disease"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blog.medcram.com\/covid-19\/covid-19-updates-pfizer-covid-19-fda-authorized-pill-paxlovid-explained-and-update-on-monoclonal-antibodies-and-omicron-variant\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blog.medcram.com\/covid-19\/covid-19-updates-pfizer-covid-19-fda-authorized-pill-paxlovid-explained-and-update-on-monoclonal-antibodies-and-omicron-variant\/","url":"https:\/\/blog.medcram.com\/covid-19\/covid-19-updates-pfizer-covid-19-fda-authorized-pill-paxlovid-explained-and-update-on-monoclonal-antibodies-and-omicron-variant\/","name":"COVID-19 Updates - Pfizer COVID 19 FDA Authorized Pill \"Paxlovid\" Explained, and an Update on Monoclonal Antibodies and the Omicron Variant. - Medcram Blog","isPartOf":{"@id":"https:\/\/blog.medcram.com\/#website"},"datePublished":"2022-01-06T05:18:33+00:00","dateModified":"2022-03-01T05:50:25+00:00","description":"Professor Roger Seheult, MD of MedCram, examines Paxlovid, how it works, and its efficacy against severe disease and hospitalization. He also takes a look at monoclonal antibodies and how they interact with the Omicron variant and can assist with avoiding hospitalization and severe illness.\u00a0","breadcrumb":{"@id":"https:\/\/blog.medcram.com\/covid-19\/covid-19-updates-pfizer-covid-19-fda-authorized-pill-paxlovid-explained-and-update-on-monoclonal-antibodies-and-omicron-variant\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blog.medcram.com\/covid-19\/covid-19-updates-pfizer-covid-19-fda-authorized-pill-paxlovid-explained-and-update-on-monoclonal-antibodies-and-omicron-variant\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blog.medcram.com\/covid-19\/covid-19-updates-pfizer-covid-19-fda-authorized-pill-paxlovid-explained-and-update-on-monoclonal-antibodies-and-omicron-variant\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blog.medcram.com\/"},{"@type":"ListItem","position":2,"name":"COVID-19","item":"https:\/\/blog.medcram.com\/category\/covid-19\/"},{"@type":"ListItem","position":3,"name":"COVID-19 Updates &#8211; Pfizer COVID 19 FDA Authorized Pill &#8220;Paxlovid&#8221; Explained, and an Update on Monoclonal Antibodies and the Omicron Variant."}]},{"@type":"WebSite","@id":"https:\/\/blog.medcram.com\/#website","url":"https:\/\/blog.medcram.com\/","name":"Medcram Blog","description":"Medcram Blog","publisher":{"@id":"https:\/\/blog.medcram.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blog.medcram.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blog.medcram.com\/#organization","name":"MedCram","url":"https:\/\/blog.medcram.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blog.medcram.com\/#\/schema\/logo\/image\/","url":"https:\/\/blog.medcram.com\/wp-content\/uploads\/2017\/05\/logo.png","contentUrl":"https:\/\/blog.medcram.com\/wp-content\/uploads\/2017\/05\/logo.png","width":152,"height":89,"caption":"MedCram"},"image":{"@id":"https:\/\/blog.medcram.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/MedCram\/","https:\/\/twitter.com\/medcramvideos","https:\/\/www.instagram.com\/medcram\/","https:\/\/www.youtube.com\/c\/medcram"]},{"@type":"Person","@id":"https:\/\/blog.medcram.com\/#\/schema\/person\/0f1abd9ef5d4bf6b5fe0b0d50b9fd9c2","name":"Betty Seheult","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blog.medcram.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/2ed8bbd19f04d10eaff8a77705d7f213?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2ed8bbd19f04d10eaff8a77705d7f213?s=96&d=mm&r=g","caption":"Betty Seheult"}}]}},"_links":{"self":[{"href":"https:\/\/blog.medcram.com\/wp-json\/wp\/v2\/posts\/1083"}],"collection":[{"href":"https:\/\/blog.medcram.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.medcram.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.medcram.com\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.medcram.com\/wp-json\/wp\/v2\/comments?post=1083"}],"version-history":[{"count":2,"href":"https:\/\/blog.medcram.com\/wp-json\/wp\/v2\/posts\/1083\/revisions"}],"predecessor-version":[{"id":1086,"href":"https:\/\/blog.medcram.com\/wp-json\/wp\/v2\/posts\/1083\/revisions\/1086"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blog.medcram.com\/wp-json\/wp\/v2\/media\/1085"}],"wp:attachment":[{"href":"https:\/\/blog.medcram.com\/wp-json\/wp\/v2\/media?parent=1083"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.medcram.com\/wp-json\/wp\/v2\/categories?post=1083"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.medcram.com\/wp-json\/wp\/v2\/tags?post=1083"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}